NovoCure (NVCR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Company background and technology

• Developed electric field-based therapy for solid tumors, initially targeting glioblastoma, with significant clinical success and broad adoption in the US and Europe.

• Profits from glioblastoma business reinvested into expanding indications, leading to new PMAs and successful phase 3 trials in lung and brain metastases.

• Positioned to expand therapy to larger patient groups in hard-to-treat cancers, with ongoing growth potential in existing markets.

Pancreatic cancer trial insights

• Phase 3 trial targeted first-line, locally advanced, non-resectable pancreatic cancer patients, adding Tumor Treating Fields (TTF) to GemAbraxane.

• Achieved statistically significant and clinically meaningful increase in overall survival, marking the first successful phase 3 trial in this population.

• Early feedback from clinicians is highly positive, with the therapy described as practice-changing and game-changing.

• Quality of life was measured, with minimal systemic toxicity and manageable skin irritation as the main adverse event.

• FDA submission expected mid-2025, with potential approval and launch by mid-2026; initial US eligible patient population estimated at 15,000.

Commercialization and market opportunity

• US launch will focus on patients eligible for TTF plus GemAbraxane, with plans to file in Europe and Japan in parallel.

• Initial therapy duration guidance is six months for pancreatic and lung indications.

• Penetration rate is uncertain but expected to be high due to lack of alternatives and strong clinical enthusiasm.

• OUS (outside US) launch plans will follow core markets, with reimbursement strategies modeled after previous launches.